Free tool
FAERS Monitor: Mekinist
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204114 or its brand name (Mekinist, Trametinib Dimethyl Sulfoxide). Reports on generic versions are filed under their own applications.
Reports
24,319
Serious
17,696
73% of reports
Hospitalization
6,629
Death reported
5,169
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia4,116
- death3,413
- malignant neoplasm progression2,070
- rash1,764
- fatigue1,538
- nausea1,512
- diarrhoea1,308
- chills1,303
- product use in unapproved indication1,091
- vomiting1,083
- off label use873
- headache771
- asthenia745
- drug ineffective686
- malaise658
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 360 |
| 2014 | 628 |
| 2015 | 1,693 |
| 2016 | 1,422 |
| 2017 | 1,760 |
| 2018 | 2,350 |
| 2019 | 2,676 |
| 2020 | 2,470 |
| 2021 | 2,414 |
| 2022 | 2,233 |
| 2023 | 2,150 |
| 2024 | 1,731 |
| 2025 | 1,525 |
| 2026 | 907 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,029,840 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 2,070 | 17.8 | 17.1 | 32,344 |
| pyrexiaSignal | 4,116 | 10.4 | 10.1 | 35,122 |
| chillsSignal | 1,303 | 9.7 | 9.2 | 10,114 |
| product use in unapproved indicationSignal | 1,091 | 3.8 | 3.6 | 2,285 |
| rashSignal | 1,764 | 3.5 | 3.4 | 3,218 |
| deathSignal | 3,413 | 3.4 | 3.3 | 6,119 |
| vomiting | 1,083 | 2.0 | 1.9 | 547 |
| diarrhoea | 1,308 | 1.8 | 1.7 | 436 |
| asthenia | 745 | 1.7 | 1.6 | 225 |
| fatigue | 1,538 | 1.7 | 1.6 | 469 |
| nausea | 1,512 | 1.7 | 1.6 | 404 |
| malaise | 658 | 1.3 | 1.2 | 46 |
| headache | 771 | 1.1 | 1.0 | 3 |
| off label use | 873 | 0.9 | 0.8 | 20 |
| drug ineffective | 686 | 0.4 | 0.4 | 491 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.